Spermosens AB (publ) INTERIM REPORT JULY – SEPTEMBER 2026

Our focus is shifting from development to go-to-market preparations

1 JULY – 30 SEPTEMBER 2026

SIGNIFICANT EVENTS DURING THE INTERIM PERIOD

1 July, 2026	Spermosens provides an update on the Generation 3 clinical study
21 July, 2026	Spermosens calls SEK 4.85 million under previously announced Capital Facility
6 August, 2026	Spermosens raises approx. SEK 4.85m in directed issue and calls EGM
6 August, 2026	Notice of Extraordinary General Meeting in Spermosens AB (publ)
20 August, 2026	Spermosens AB (publ) INTERIM REPORT APRIL – JUNE 2026
1 September, 2026	Bulletin from Extraordinary General Meeting in Spermosens AB (publ)

SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD

20 October, 2026	Spermosens presents JUNO-*Checked* at ASRM 2026 in Baltimore
9 November, 2026	Leading Australian fertility group Genea to run first independent clinical study of JUNO-*Checked*

FINANCIAL INFORMATION

Amounts in SEK thousand	2026 Q3	2025 Q3	2026 Q1-Q3	2025 Q1-Q3	2025 Full-Year	Rolling 12 mth
Net sales	–	–	–	–	–	–
Operating profit/loss	-2 377	-2 355	-7 338	-7 080	-9 201	-9 459
- Whereof activated work for own account	–	144	488	1 061	2 387	1 814
Cash and cash equivalents	4 026	12 862	4 026	12 862	4 492	4 026
Total Cash flow			-2 979	6 171	6 177	-2 973
Equity end of period	29 895	34 523	29 895	34 523	12 692	29 895
Balance sheet total	31 136	35 587	31 136	35 587	26 105	31 136
Equity/assets ratio,%	96	97	96	97	49	96
Liquidity ratio,%	387	927	387	927	43	387
No. of shares	3 492 301 168	3 173 024 065	3 492 301 168	3 173 024 065	3 492 301 168	1 696 939 755
Weighted average number of shares, adjusted for dilution effect (thousands)	3 492 301 168	3 173 024 065	3 492 301 168	2 287 895 595	2 537 686 452	3 014 993 810

Earnings per share, SEK	-0,001	-0,001	-0,002	-0,003	-0,004	-0,003
Number of employees at end of period	4	4	4	4	4	4

CEO STATEMENT

Couples start fertility treatment without knowing whether the sperm can bind to the egg, and many experience failed treatment. In our first clinical study, around a quarter of normal-looking sperm samples had low binding capacity. No one has ever been able to answer this vital question about sperm-egg binding. JUNO-*Checked* is designed to answer it. In our second clinical study, Generation 3 is being tested in a real clinical setting. The study is on track, the new generation is proving robust and we look forward to the results.

The right partners are decisive for unlocking the value of JUNO-*Checked*. We have established new contacts with several serious companies, and they like what we present. Last month we attended ASRM in Baltimore, USA, the annual congress of the American Society for Reproductive Medicine, where we had many valuable meetings, far more than expected. We have signed a collaboration framework agreement with Genea, one of Australia's leading fertility groups, which plans to run a clinical study of JUNO-*Checked*. We are following up and discussing partnership models, aiming for commercial agreements.

86 patients have been tested in the second study, about twice as many as before the summer break. We see low variation between sensors, we have extended their shelf life at room temperature to more than six months, and we can manufacture them efficiently. The sensors are easy to use, and the time to result has been cut to 30 minutes. Our ambition to complete the second study by year end remains, and we have the flexibility to extend it to collect more data and refine the test conditions for routine clinical use.

The collaboration with Genea is an important step. The study aims to strengthen the evidence, test JUNO-*Checked* in a large clinic group with an international reputation and build confidence in our product. Genea expects to start the study next year, when approvals are in place. The agreement foresees commercial negotiations once the study milestones are reached.


Several companies we meet have global reach, and in Japan a contact on the ground has introduced us to a larger company. Our dialogues have given us feedback and advice on pricing and positioning, such as how to reduce unnecessary IUI cycles by directing couples earlier to ICSI treatment, and on the regulatory pathway and faster routes to market. We are in talks with partners that have the reach and capabilities to bring JUNO-*Checked* to market, on terms that work for both sides.

The capital facility of SEK 4.85 million before issue costs extends our runway into the first quarter of 2027, and the TO6 warrants, exercisable from 30 November, may bring additional funding. Partnership agreements are the key to long-term funding, revenue and commercial success.

Our focus is shifting from development to go-to-market preparations. Potential partners have shown genuine, qualified interest and a willingness to discuss further, and they see a clear need for a product like JUNO-*Checked*. We are building their input into our plans.

The investors who stand behind us believe in the company and see its potential. I am grateful for that conviction. We are working to make it a success for all our shareholders.





Tore Duvold, CEO of Spermosens